Relative Drug Exposures Of Two Formulations of PF-02341066
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over,
single-dose study employing administration of two PF-02341066 formulations in the fasted
state to healthy adult volunteers.